NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,168.65 +339.72 (+2.02%) CRUDE OIL
83.53 +0.17 (+0.20%) GOLD FUTURES
2,341.70 -0.40 (-0.02%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,546.27 -17.77 (-0.03%)
Quince Therapeutics, Inc. (QNCX)
After hours:
| Previous close | 1.0600 |
| Open | 1.0500 |
| Bid | 1.0700 x 100 |
| Ask | 1.1400 x 100 |
| Day's range | 1.0500 - 1.1100 |
| 52-week range | 0.8400 - 1.7400 |
| Volume | |
| Avg. volume | 70,254 |
| Market cap | 47.969M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8400 |
| Earnings date | 13 May 2024 - 28 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., April 01, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
ZacksThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Quince Therapeutics and XBiotech are included in this Analyst Blog.
Business WireQuince Therapeutics Launches Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., February 22, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice.
